Aldesleukin
Aldesleukin is a human recombinant interleukin-2
derivative that’sused to treat metastatic renal cell carcinoma.
After I.V. administration of aldesleukin, about 30%
is absorbed into plasma and about 70% is absorbed rapidly by the liver, kidneys,
and lungs. The drug is excreted primarily by the kidneys.
The exact antitumor mechanism of action of
aldesleukin is un-known. The drug may stimulate an immunologic reaction against
the tumor.
Aldesleukin is used to treat metastatic renal
cell carcinoma. It may also be used in the treatment of Kaposi’s sarcoma and
metastatic melanoma.
Aldesleukin will interact with other drugs.
§
Concomitant
administration of aldesleukin and drugs with psy-chotropic properties (such as
opioids, analgesics, antiemetics, sedatives, and tranquilizers) may produce
additive CNS effects.
§
Glucocorticoids may
reduce aldesleukin’s antitumor effects.
§
Antihypertensive drugs
may potentiate aldesleukin’s hypoten-sive effects.
§
Concurrent therapy with
drugs that are toxic to the kidneys (such as aminoglycosides), bone marrow
(such as cytotoxic chemotherapy drugs), heart (such as doxorubicin), or liver
(such as methotrexate or asparaginase) may increase toxicity to these organs. (See
Adverse reactions to aldesleukin.)
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.